ERBB2 and breast carcinoma: Another early-phase study, the DS3201-324 phase Ib trial, is evaluating the combination of valemetostat and T-DXd in patients with HER2-low breast cancer, gastric cancer (GC)/gastroesophageal junction (GEJ) adenocarcinoma, and NSCLC.